# Pegvisomant (Somavert)

> Pegylated GH receptor antagonist for acromegaly.

Source: https://peptides.cafe/peptide/pegvisomant
Category: GH Receptor Antagonist · Endocrine
Tag: FDA-Approved · Endocrine

## Mechanism
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.

## Research areas
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs

## Common research protocols
- Daily SC: Loading dose 40 mg SC, then 10–30 mg SC daily titrated to IGF-1.

## Study summaries
- "Pegvisomant long-term acromegaly control" — Lancet (2001): IGF-1 normalization in >90% on adequate doses.

## Considerations
- FDA-approved.
- Monitor LFTs; tumor monitoring via MRI required.
- Lipohypertrophy at injection sites.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.